Free tool
FAERS Monitor: Claritin Reditabs
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021993 or its brand name (Claritin Reditabs, Loratadine). Reports on generic versions are filed under their own applications.
Reports
104,790
Serious
49,542
47% of reports
Hospitalization
23,065
Death reported
4,558
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective12,371
- fatigue6,616
- nausea5,815
- headache5,349
- diarrhoea4,809
- dyspnoea4,809
- off label use4,642
- dizziness4,320
- pain4,066
- rash3,439
- pruritus3,375
- cough3,094
- vomiting2,963
- arthralgia2,904
- somnolence2,866
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 966 |
| 2005 | 1,079 |
| 2006 | 1,075 |
| 2007 | 947 |
| 2008 | 1,078 |
| 2009 | 1,328 |
| 2010 | 1,645 |
| 2011 | 2,034 |
| 2012 | 3,276 |
| 2013 | 4,246 |
| 2014 | 4,999 |
| 2015 | 7,321 |
| 2016 | 8,813 |
| 2017 | 8,781 |
| 2018 | 7,751 |
| 2019 | 7,831 |
| 2020 | 7,033 |
| 2021 | 6,297 |
| 2022 | 6,122 |
| 2023 | 5,516 |
| 2024 | 6,029 |
| 2025 | 5,967 |
| 2026 | 4,655 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,949,369 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| somnolenceSignal | 2,866 | 2.9 | 2.8 | 3,508 |
| coughSignal | 3,094 | 2.2 | 2.2 | 2,098 |
| drug ineffective | 12,371 | 1.9 | 1.9 | 5,501 |
| pruritus | 3,375 | 1.8 | 1.7 | 1,139 |
| dizziness | 4,320 | 1.7 | 1.7 | 1,394 |
| headache | 5,349 | 1.7 | 1.7 | 1,642 |
| fatigue | 6,616 | 1.7 | 1.7 | 2,015 |
| dyspnoea | 4,809 | 1.7 | 1.7 | 1,447 |
| rash | 3,439 | 1.6 | 1.5 | 758 |
| diarrhoea | 4,809 | 1.5 | 1.5 | 818 |
| nausea | 5,815 | 1.5 | 1.4 | 927 |
| arthralgia | 2,904 | 1.4 | 1.4 | 343 |
| pain | 4,066 | 1.3 | 1.3 | 342 |
| vomiting | 2,963 | 1.3 | 1.2 | 169 |
| off label use | 4,642 | 1.1 | 1.0 | 19 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.